Table 1.

Characteristics of 9 RCTs included in the meta-analysis.

						Intervention
Studies	Sample size (T/C)	Mean age, y (SD)	Design	Diagnostic criteria for insomnia	Diagnostic criteria for anxiety	Treatment	Control	Duration of intervention, wk	Adverse events	Outcome measures
Deng, 2017[42]	50/45	T: 41.66 (3.12)C: 43.0 (6.15)	2 Parallel arms	CCMD-3, GDTCIDCM	CCMD-3, GDTCIDCM	Modified XYS(1 dose/400 mL/day)	Mirtazapine Tablets(30 mg, qd)	8	Y	CEIT, HAMA, PSQI
Li, 2016[59]	40/40	T: 42.39 (5.17)C: 42.45 (5.26)	2 parallel arms	CCMD-3, CDTEDSTCM, GCRNCM	CCMD-3, CDTEDSTCM, GCRNCM	Modified XYS(2 mg, tid) + C	Estazolam tablets(1 mg, qd)	6	Y	CEIT, SSSI, SAS
Chen and Zhou2019[54]	26/26	T: 44.04 (10.94)C: 46.50 (12.50)	2 Parallel arms	CCMD-3, CDTEDSTCM, GDTCIDCM	CCMD-3, CDTEDSTCM, GDTCIDCM	Modified XYS(4 dose/day) + C	Mirtazapine Tablets(30 mg, qd)	2	Y	CEIT, AEs, PSQI, SSSI
Huang and Xiang, 2014[52]	34/28	T: 43.5 (2.5)C: 41.5 (2.5)	2 Parallel arms	CCMD-3	CCMD-3	Modified XYS(1 dose/day)	Estazolam tablets(1 mg, qd)	4	N	CEIT, SAS
Hou, 2014[55]	30/30	T: 39 (12.55)C: 42 (11.76)	2 Parallel arms	CCMD-3, CDTEDSTCM, PSQI	CCMD-3, CDTEDSTCM, HAMA	Modified XYS(1 dose/day) + C	Estazolam tablets(1 mg, qd)	4	Y	CEIT, CEAT, CEAH, CEIP, HAMA, PSQI, SSSI, SSSA, TESS
Li, 2019[56]	30/30	T: 39.93 (10.27)C: 41.03 (10.31)	2 Parallel arms	CCMD-3, CDTEDSTCM	CCMD-3, CDTEDSTCM	Modified XYS(1 dose/day) + C	Zopiclone tablets(7.5 mg, qd)	4	N	CEAH, CEIP, HAMA, PSQI, SSSI, SSSA
Xue and Guo, 2009[53]	44/43	21-68	2 parallel arms	CCMD-3, PSQI	CCMD-3, HAMA	Modified XYS(1 dose/day)	Mirtazapine Tablets(10–45 mg, qd)	5	Y	PSQI, HAMA
Tang, 2018[57]	40/40	T: 44.7 (4.1)C: 45.9 (3.2)	2 parallel arms	CCMD-3, PSQI	CCMD-3, HAMA	Modified XYS(1 dose/day) + C	Eszopiclone tablets (2 mg, qd) + ZAC (1.8 g, qd)	15	N	PSQI, SAS
Liu, 2017[49]	53/52	T: 26.8 (5.5)C: 43.5 (5.6)	2 parallel arms	CCMD-3, PSQI	CCMD-3, SAS	Modified XYS(1 dose/day) + C	Estazolam tablets(1 mg, qd)	6	N	PSQI, SAS